HUIYU PHARMACEUTICAL: Injectable Paclitaxel (Albumin-Bound) Obtains Overseas Listing License
I'm PortAI, I can summarize articles.
HUIYU PHARMACEUTICAL announced that its subsidiary Seacross Pharma (Europe) Ltd. has obtained marketing authorization for injectable paclitaxel (albumin-bound) from the regulatory authorities in the Netherlands, Ireland, Finland, and Sweden. The drug is indicated for the treatment of adult patients with metastatic breast cancer, metastatic pancreatic adenocarcinoma, and non-small cell lung cancer
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments